TerrAscend (TSNDF) Net Income towards Common Stockholders (2021 - 2026)
TerrAscend's (TSNDF) quarterly Net Income towards Common Stockholders came in at -$1.2 million in Q1 2026, up 74.48% year-on-year from -$673434.6 in Q1 2025, and down 128.59% on a QoQ basis from $4.1 million in Q4 2025.
TerrAscend (TSNDF) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$1.2 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 74.48% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$53.4 million, a 5.3% decrease from a year earlier, with the FY2025 full-year figure at -$56.8 million, down 9.78% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$1.2 million, down from $4.1 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for TSNDF reached as high as $4.1 million in Q4 2025 and fell as low as -$54.7 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged -$12.0 million across 5 years, with a median of -$4.6 million in 2025.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 110.13% in 2025 and fell as far as 86977.08% in 2025.
- Year by year, Net Income towards Common Stockholders stood at -$10.6 million in 2022, then plunged by 417.02% to -$54.7 million in 2023, then climbed by 25.74% to -$40.6 million in 2024, then soared by 110.13% to $4.1 million in 2025, then plunged by 128.59% to -$1.2 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$1.2 million in Q1 2026, $4.1 million in Q4 2025, and -$14.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 90.13 Bn | 88.27 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 57.00 Mn |
| 10 | TerrAscend | 168.49 Mn | 168.02 Mn | 34.60 Mn | -1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.18 Mn |
| Dec 31, 2025 | 4.11 Mn |
| Sep 30, 2025 | -14.65 Mn |
| Jun 30, 2025 | -41.70 Mn |
| Mar 31, 2025 | -4.60 Mn |
| Dec 31, 2024 | -40.59 Mn |
| Sep 30, 2024 | -5.58 Mn |
| Jun 30, 2024 | 48,000.00 |
| Mar 31, 2024 | -14.85 Mn |
| Dec 31, 2023 | -54.66 Mn |
| Sep 30, 2023 | -232,000.00 |
| Jun 30, 2023 | -621,000.00 |
| Mar 31, 2023 | -3.59 Mn |
| Dec 31, 2022 | -10.57 Mn |
| Sep 30, 2022 | -10.42 Mn |
| Jun 30, 2022 | -2.70 Mn |
| Mar 31, 2022 | -2.26 Mn |
| Dec 31, 2021 | 2.35 Mn |
| Sep 30, 2021 | 55.84 Mn |
| Jun 30, 2021 | -29.66 Mn |